Table 3.
Recent clinical results of NK cell infusions (2019–2021).
| Cell Source | NK Cell Preparation | Interventions | Malignancy | Response | Phase | Patient Number | Patient Age | Trial Identifiers |
|---|---|---|---|---|---|---|---|---|
| Haploidentical NK | K562-mb21-41BBL | Before treatment with chemotherapy | AML | MRD remission in 9 patients | - | 20 | ≥18 | - [88] |
| Haploidentical NK | K562-mb21-41BBL | Before treatment with chemotherapy | Relapsed/Refractory AML | 78.6% overall response; 50.0% CR; CNS responses in 4 patients | I/II | 13 | 2–59 |
NCT02809092 [129] |
| UCB-NK | K562-mb21-41BBL; Modification: anti-CD19 CAR, IL-15, iC9 | Before treatment with lymphodepleting chemotherapy | CD19+lymphoma | CR in 7 patients; Richter’s transformation remission in 1 patient | I/II | 11 | 47–70 |
NCT03056339 [13] |
| Haploidentical NK | None | Before treatment with lymphodepleting chemotherapy; After treatment with rhIL-15 intravenously (0.3–1.0 mg/kg) | Refractory AML | Robust NK expansion in 36% of patients at day 14; CR in 32% of patients | I | 26 | ≥18 |
NCT01385423 [202] |
| Haploidentical NK | None | Before treatment with lymphodepleting chemotherapy and rhIL-2 subcutaneously | Pediatric AML | None | II | 21 | 0–15 |
NCT00703820 [204] |
| Haploidentical NK | K562-mb15-41BBL | Before treatment with lymphodepleting chemotherapy and rhIL-2 subcutaneously | Pediatric AML | CR in 6 patients | II | 7 | 0–15 |
NCT02763475 [14] |
| Autologous NK | TKD/IL2-activated | Before treatment with RCT | NSCLC | RCT + NK group (n = 8): 67% 1-year probabilities for PFS | II | 16 | 56–76 | - [4] |
| Autologous NK | NK in vitro preparation kit | Before treatment with IRE | PLC | IRE + NK group (n = 18): median PFS (15.1 months), median 1-year OS (23.2 months) | II | 40 | 20–80 |
NCT03008343 [89] |
| Autologous NK | K562-mb21-41BBL | None | Recurrent pediatric MB and ependymoma | Progressive disease in 9 patients; transient radiographic response in 1 patient | I | 9 | 8–18 | - [206] |
UCB, umbilical cord blood; AML, acute myeloid leukemia; GBM, glioblastoma multiforme; NSCLC, non-small cell lung cancer; PLC, primary liver cancer; MB, medulloblastoma; RCT, radiochemotherapy; IRE, irreversible electroporation; MRD, minimal residual disease; CR, complete remission; PFS, progression-free survival; OS, overall survival; CNS, central nervous system; CRS, cytokine release syndrome.